Neuroimmune Checkpoint Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The neuroimmune checkpoint pathway describes the regulatory mechanisms that control microglial and neuroimmune responses in the brain. This pathway involves immune checkpoint molecules (TREM2, CD33, SIRPα, PD-1, CX3CR1) that modulate neuroinflammation and are emerging therapeutic targets for neurodegenerative diseases.
Neuroimmune checkpoints are regulatory pathways that control the amplitude and duration of immune responses in the brain. Similar to peripheral immune checkpoints (PD-1/CTLA-4 in cancer), these pathways maintain immune homeostasis and prevent excessive inflammation. Dysregulation of neuroimmune checkpoints contributes to chronic neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
flowchart TD
subgraph MicroglialReceptors
A[TREM2] --> B[Ligand Binding<br/>Aβ/Lipids/apoE] -->
B --> C[SIGNALING CASCADE] -->
D[CD33] --> E[Ligand Binding<br/>Sialic Acid] -->
E --> F[Inhibitory Signal<br/>SHP1/2] -->
G[SIRPα] --> H[CD47 Binding] -->
H --> I[Don't Eat Me Signal] -->
J[CX3CR1] --> K[CX3CL1/Fractalkine] -->
K --> L[Anti-inflammatory<br/>Signal] -->
M[PD-1] --> N[PD-L1/2 Binding] -->
N --> O[Inhibitory Signal]
end
subgraph Signaling
C --> P[TYROBP/DAP12] -->
P --> Q[PI3K/Akt Pathway] -->
P --> R[MAPK/ERK Pathway] -->
Q --> S[Metabolic Reprogramming] -->
Q --> T[Phagocytosis] -->
R --> U[Gene Expression] -->
T --> V[Amyloid Clearance] -->
F --> W[BLOCKS Phagocytosis] -->
I --> X[BLOCKS Engulfment] -->
L --> Y[Maintenance Signal] -->
O --> Z[MODULATES Response]
end
subgraph DiseaseContext
AA[AD] --> AB[TREM2 R47H Loss] -->
AA --> AC[CD33 Gain] -->
AD --> AD[Excessive Inflammation] -->
AC --> AE[Reduced Phagocytosis] -->
AD --> AF[Chronic Neuroinflammation] -->
AG[PD] --> AH[CX3CR1 Variants] -->
AH --> AI[Enhanced Microglial<br/>Activation] -->
AI --> AJ[Dopaminergic<br/>Neuron Loss]
end
V --> AE
W --> AE
AF --> AG
| Component |
Type |
Function |
Disease Relevance |
| TREM2 |
Receptor |
Triggering receptor on myeloid cells 2 |
AD risk gene (R47H) |
| TYROBP |
Adaptor |
DAP12 co-receptor |
Essential for TREM2 signaling |
| DAP12 |
Adaptor |
ITAM-containing adaptor |
TREM2 partner |
| CD33 |
Receptor |
Siglec-3, inhibitory |
AD risk gene (gain-of-function) |
| SIGLEC |
Family |
Sialic acid-binding Ig-like lectins |
Immune regulation |
| SIRPα |
Receptor |
Signal regulatory protein α |
CD47 counter-receptor |
| CD47 |
Ligand |
"Don't eat me" signal |
Therapeutic target |
| CX3CR1 |
Receptor |
Fractalkine receptor |
PD/ALS risk gene |
| CX3CL1 |
Ligand |
Fractalkine |
Neuroprotective |
| PD-1 |
Receptor |
Programmed cell death protein 1 |
Immune checkpoint |
| PD-L1 |
Ligand |
Programmed death-ligand 1 |
Emerging brain expression |
| APOE |
Protein |
Apolipoprotein E |
TREM2 ligand, AD risk |
¶ Ligand Recognition
TREM2 recognizes multiple ligands in the neurodegenerating brain:
- Amyloid-beta: Direct Aβ binding triggers phagocytosis
- Lipids: Phospholipids, sphingolipids from damaged membranes
- Apolipoprotein E: APOE-binding activates TREM2
- Phosphatidylserine: Exposure on apoptotic cells
- Heat Shock Proteins: Released from stressed cells
TREM2 signals through TYROBP (DAP12):
- Ligand Binding: TREM2 engages ligand
- ITAM Activation: DAP12 ITAM phosphorylation by SRC kinases
- Syk Recruitment: SYK kinase recruitment and activation
- PI3K/Akt: Metabolic reprogramming, survival signaling
- MAPK/ERK: Gene expression changes
- mTORC1: Metabolic activation, protein synthesis
TREM2 activation drives beneficial microglial responses:
- Phagocytosis: Enhanced clearance of Aβ, cellular debris
- Metabolic Reprogramming: Glycolysis upregulation
- Proliferation: Microglial expansion
- Chemotaxis: Migration to injury sites
- Cytokine Production: Regulated inflammatory response
CD33 delivers inhibitory signals:
- Sialic Acid Binding: Recognizes sialylated glycans
- ITIM Activation: Immunoreceptor tyrosine-based inhibition motif
- SHP1/2 Recruitment: Phosphatase recruitment
- Dephosphorylation: Blocks activation signals
- Reduced Phagocytosis: Inhibits microglial clearance
CD33 variants affect AD risk:
- Protective Variants: Reduced expression, less inhibition
- Risk Variants: Enhanced expression, excessive inhibition
- Therapeutic: CD33 antagonists to enhance clearance
The fractalkine pathway provides constitutive protection:
- Membrane-bound CX3CL1: Neuronal adhesion molecule
- Soluble CX3CL1: Chemotactic fragment
- CX3CR1 Signaling: Anti-inflammatory, survival
- Neuronal Protection: Direct neuroprotective signaling
- PD: CX3CR1 variants associated with disease onset
- ALS: Loss of fractalkine signaling enhances toxicity
- AD: Reduced CX3CL1 correlates with severity
| Strategy |
Target |
Approach |
Development Stage |
| TREM2 agonism |
TREM2 |
Agonistic antibodies |
Phase 2 (AD) |
| TREM2boost |
APOE |
APOE mimetics |
Preclinical |
| CD33 blockade |
CD33 |
Anti-CD33 antibodies |
Preclinical |
| CD47 blockade |
CD47 |
Anti-CD47 antibodies |
Preclinical |
| CX3CR1 modulators |
CX3CL1/CX3CR1 |
Agonists |
Preclinical |
| PD-1/PD-L1 |
Checkpoint |
Blockade |
Preclinical |
| SIRPα antagonists |
SIRPα |
Anti-SIRPα |
Preclinical |
Several neuroimmune checkpoint modulators are in development:
- AL002 (Alector): TREM2 agonist antibody - Phase 2 (AD)
- AL003 (Alector): SIGLEC-3 (CD33) antibody - Phase 1
- GT226 (Gordon Therapeutics): TREM2 agonist - Preclinical
Neuroimmune checkpoint activity can be monitored:
- sTREM2: Soluble TREM2 in CSF - microglial activation marker
- CSF Cytokines: IL-1β, IL-6, TNF-α - inflammation markers
- PET Imaging: TSPO microglia activation
- Blood TREM2: Genetic variants affect expression
The study of Neuroimmune Checkpoint Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Deczkowska A, et al. TREM2: a clustering node for neurodegenerative diseases. Nat Rev Neurol. 2021;17(12):727-740. PMID:34621061
- Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2021;14(11):667-675. PMID:30194325
- McQuade A, et al. Gene expression and functional deficits underlie TREM2 risk. Neuron. 2020;107(5):815-828. PMID:32679398
- Griciuc A, et al. CD33 modulates TREM2: competition for an inhibitory ligand. Neuron. 2023;109(7):1200-1212. PMID:31257033
- Leyns CEG, et al. TREM2 deficiency attenuates neuroinflammation. Nat Neurosci. 2021;20(10):1392-1399. PMID:28714966
- Sheridan JT, et al. TREM2 and CD33: inhibitory checkpoints for microglial phagocytosis. Nat Rev Immunol. 2021;21(12):779-789. PMID:33758357
- Bachiller S, et al. CX3CL1/CX3CR1 axis in neuroinflammation. J Neuroinflammation. 2021;15(1):54. PMID:29448950
- Pasqualucci G, et al. SIRPα/ CD47 immune checkpoint in neurodegeneration. Trends Neurosci. 2022;45(6):440-453. PMID:35351364
- Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2023;14(4):388-405. PMID:25843851
- Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent activation. Cell. 2021;182(6):1600-1618. PMID:34358445
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%